Royalty Pharma PLC (FRA:RPD)
€ 47.47 +0.17 (+0.35%) Market Cap: 21.95 Bil Enterprise Value: 31.25 Bil PE Ratio: 31.34 PB Ratio: 3.62 GF Score: 70/100

Royalty Pharma PLC at TD Cowen Healthcare Conference Transcript

Mar 03, 2026 / 06:10PM GMT
Release Date Price: €39.57 (+2.06%)
Michael Nedelcovych
Cowen and Company LLC - Equity Analyst

Welcome, everyone. Thanks for joining us. My name is Mike Nedelcovych. I'm part of TD Cowen's Pharmaceuticals Research team, and I'm very pleased to be joined by top management from Royalty Pharma, Terry Coyne, who is EVP and CFO; and Marshall Urist, who is an EVP and the Head of Research and Investments. Thank you for joining us.

Terrance Coyne
Royalty Pharma PLC - Chief Financial Officer

Thanks, Mike.

Marshall Urist
Royalty Pharma PLC - Head of Research & Investments

Thanks for having us.

Questions & Answers

Michael Nedelcovych
Cowen and Company LLC - Equity Analyst

So Royalty Pharma has a phenomenal portfolio. There's a ton to talk about. I actually want to start though with an announcement you made recently vis-a-vis your ambitions in China and Asia more broadly. You hired a Head of Asia.

It seemed like an impressive hire and quite the coup. Maybe you could tell us a little bit

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot